Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02339922 · OUTCOME

Tumor Expression of Cluster of Differentiation 68, Nuclear Transcription Factor Kappa-B, p65, p27, and Proteasome Subunit, Alpha-type, 5 by Immunohistochemistry

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma · Source last updated 2026-07-01

This outcome was registered, but no numerical results were posted in the captured record.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Up to 5 years

What was measured

Will be correlated with response to ixazomib citrate and ixazomib citrate plus rituximab.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denom Units Selected
Participants
description
Will be correlated with response to ixazomib citrate and ixazomib citrate plus rituximab.
reporting Status
NOT_POSTED
time Frame
Up to 5 years
title
Tumor Expression of Cluster of Differentiation 68, Nuclear Transcription Factor Kappa-B, p65, p27, and Proteasome Subunit, Alpha-type, 5 by Immunohistochemistry
type
OTHER_PRE_SPECIFIED

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice